

Maternal Serum Screening, Integrated, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

 Patient:
 Client:
 ARUP Test Code: 3000149

 DOB:
 Age:
 Sex:

DOB: Age: Sex:


Patient Identifiers: Collection Date:
Physician: Received in lab:

Visit Number (FIN):

Interpretation: SCREEN POSITIVE

Follow-up for risk of open spina bifida is suggested

Neural Tube Defects (NTD): Positive




Down syndrome (DS): Negative

Risk before test: **1 in 756**Risk after test: **1 in 13500**Before

After


1/100000 1/10000 1/10000



Completion Date:

Trisomy 18 (T18): Negative

Risk before test: 1 in 2950 Risk after test: <1 in 10800





Comments:

The risk of open neural tube defects is greater than the screening cut-off based on AFP MoM and/or pre-test risk factors. Other outcomes of positive screens include normal pregnancy, under-estimated gestational age, multiple gestation, ventral wall defects, and imminent or current fetal demise. Genetic counseling, level II fetal ultrasound, and if clinically indicated, amniocentesis are recommended. If you have questions regarding this screen, please call Genetics at 800-242-2787 ext 2141.

The risk of Down syndrome is less than the screening cut-off.

The risk of trisomy 18 is less than the screening cut-off.

Marker	Measurement	MoM
AFP	140 ng/mL	3.75
uE3	1.87 ng/mL	1.29
hCG	16930 IU/L	0.69
DIA	146 pg/mL	1.05
PAPP-A	715.5 ng/mL	0.60
NT	Not Done	Not Done









Patient:

ARUP Accession: 23-080-157350

Maternal Serum Screening, Integrated, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A

Patient: | Date of Birth: | Sex: | Physician: Patient Identifiers: | Visit Number (FIN):

<u>PAPP-A Maternal Compliance Statement:</u> This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Maternal Screen Interpretation Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Patient Information Used in Risk Calculations

Maternal Age at Delivery: 30.1 yr

Maternal Weight: 84.0 kg

Estimated Due Date: 08-24-23

Gestational Age at Draw: 17 wks, 5 days

Number of Fetuses: Singleton
Maternal Race: Nonblack

Medication-Dependent Maternal Diabetes: No
Current Smoker: No
Family History of Neural Tube Defects: No
Family History of Aneuploidy: No

Specimen: Initial sample

Crown Rump Length: 80.3 mm

Sonographer Certification #: Not_applicable
Sonographer Name: Not Applicable

Ultrasound Date: 02-21-23

Reference Information

The following links or information offer complete and up to date information about this test, including access to ARUP Consult™ disease topics and other supplemental resources.

- Maternal Serum Screening, Integrated, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (http://ltd.aruplab.com/tests/pub/3000149)
- Prenatal Aneuploidy Screening (https://www.aruplab.com/genetics/tests/prenatal)
- Additional Technical Information (http://ltd.aruplab.com/Tests/Pdf/311)









Patient:

ARUP Accession: 23-080-157350